Regulation of the ubiquitin-conjugating enzyme hHR6A by CDK-mediated phosphorylation
2002; Springer Nature; Volume: 21; Issue: 8 Linguagem: Inglês
10.1093/emboj/21.8.2009
ISSN1460-2075
Autores Tópico(s)Cancer-related Molecular Pathways
ResumoArticle15 April 2002free access Regulation of the ubiquitin-conjugating enzyme hHR6A by CDK-mediated phosphorylation Boris Sarcevic Corresponding Author Boris Sarcevic Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, NSW, 2010 Australia Search for more papers by this author Amanda Mawson Amanda Mawson Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, NSW, 2010 Australia Search for more papers by this author Rohan T Baker Rohan T Baker Molecular Genetics Group, John Curtin School of Medical Research, Australian National University, Canberra, ACT, 2601 Australia Search for more papers by this author Robert L Sutherland Robert L Sutherland Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, NSW, 2010 Australia Search for more papers by this author Boris Sarcevic Corresponding Author Boris Sarcevic Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, NSW, 2010 Australia Search for more papers by this author Amanda Mawson Amanda Mawson Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, NSW, 2010 Australia Search for more papers by this author Rohan T Baker Rohan T Baker Molecular Genetics Group, John Curtin School of Medical Research, Australian National University, Canberra, ACT, 2601 Australia Search for more papers by this author Robert L Sutherland Robert L Sutherland Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, NSW, 2010 Australia Search for more papers by this author Author Information Boris Sarcevic 1, Amanda Mawson1, Rohan T Baker2 and Robert L Sutherland1 1Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, NSW, 2010 Australia 2Molecular Genetics Group, John Curtin School of Medical Research, Australian National University, Canberra, ACT, 2601 Australia *Corresponding author. E-mail: [email protected] The EMBO Journal (2002)21:2009-2018https://doi.org/10.1093/emboj/21.8.2009 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Cell cycle progression in eukaryotes is mediated by phosphorylation of protein substrates by the cyclin-dependent kinases (CDKs). We screened a cDNA library by solid-phase phosphorylation and isolated hHR6A as a CDK2 substrate. hHR6A is the human homologue of the product of the Saccharomyces cerevisiae RAD6/UBC2 gene, a member of the family of ubiquitin-conjugating enzymes. hHR6A is phosphorylated in vitro by CDK-1 and -2 on Ser120, a residue conserved in all hHR6A homologues, resulting in a 4-fold increase in its ubiquitin-conjugating activity. In vivo, hHR6A phosphorylation peaks during the G2/M phase of cell cycle transition, with a concomitant increase in histone H2B ubiquitylation. Mutation of Ser120 to threonine or alanine abolished hHR6A activity, while mutation to aspartate to mimic phosphorylated serine increased hHR6A activity 3-fold. Genetic complementation studies in S.cerevisiae demonstrated that hHR6A Ser120 is critical for cellular proliferation. This is the first study to demonstrate regulation of UBC function by phosphorylation on a conserved residue and suggests that CDK-mediated phosphorylation of hHR6A is an important regulatory event in the control of cell cycle progression. Introduction In eukaryotes, cell cycle progression is mediated by the sequential activation and inactivation of the cyclin-dependent kinases (CDKs). Active CDKs consist of a protein kinase subunit whose catalytic activity is dependent on the association with a regulatory cyclin subunit (Pines, 1993). In mammalian cells, mitogenic stimulation results in the expression of D-type cyclins which associate with either CDK4 or CDK6 to mediate G1 phase cell cycle progression. Progression from G1 to S phase is controlled by cyclin E–CDK2, with cyclin A–CDK2 mediating S phase progression. Cyclin A–CDC2 is required during the G2 phase of the cell cycle and, finally, transition throughout mitosis is regulated by cyclin B–CDC2 (Grana and Reddy, 1995). Although the mechanisms of cyclin–CDK regulation have largely been unveiled, our understanding of CDK substrates and how phosphorylation alters their function to execute cell cycle transitions remains to be fully defined. In the present study, we have used an in vitro phosphorylation screening method to identify the ubiquitin-conjugating enzyme (UBC), hHR6A, as a CDK substrate. The ubiquitin pathway plays an important role in the regulation of a broad array of biological processes such as control of cell cycle regulation, signal transduction pathways, apoptosis and DNA repair (Hershko and Ceichanover, 1998). This pathway involves conjugation of the conserved 76 amino acid ubiquitin peptide to substrate proteins via a three-step cascade, which then targets the protein for proteolytic degradation by the 26S proteasome (Ciechanover, 1998; Hershko and Ceichanover, 1998). In this cascade, ubiquitin initially is activated by forming a thioester bond between its C-terminal glycine and a cysteine in the ubiquitin-activating enzyme (E1). After activation, ubiquitin is transferred to a cysteine on an E2 UBC and subsequently covalently attached to the substrate protein either directly, or with the cooperation of a ubiquitin protein ligase (E3). This covalent attachment involves the formation of an isopeptide bond with the N-terminus or an ϵ-NH2 group of an internal lysine residue. A central role in the ubiquitin pathway is played by the family of UBC enzymes, which in the yeast Saccharomyces cerevisiae comprises at least 13 members (Ciechanover, 1998). An example of the importance of this family of enzymes is exemplified by the S.cerevisiae Rad6 protein. Genetic studies have shown that yeast rad6 mutants display a pleiotropic phenotype including defects in DNA repair, proteolysis of N-end rule protein substrates, cellular proliferation, cell cycle progression and an inability to sporulate (Watkins et al., 1993; Lawrence, 1994), which are all dependent on its ubiquitin-conjugating activity (Sung et al., 1990). Rad6 can ubiquitylate histones in vitro, and ubiquitylation of histone H2B in S.cerevisiae is Rad6 dependent (Robzyk et al., 2000). In mice and humans, two homologues of RAD6 have been identified, termed HR6A (homologue of RAD6A) and HR6B (homologue of RAD6B) (Koken et al., 1991; Roest et al., 1996). Studies with the human RAD6 homologues show that both can replace the DNA repair functions of S.cerevisiae Rad6 (Koken et al., 1991). In whole animal studies, loss of the mouse HR6B gene caused male infertility due to impaired spermatogenesis (Roest et al., 1996), which was postulated to result from defects in histone ubiquitylation and chromatin modification (Koken et al., 1996). One major function of Rad6 is regulating cell cycle progression, since S.cerevisiae that lack Rad6 display defects in transit through the S/G2 phase of the cell cycle (Ellison et al., 1991). Our studies show that hHR6A is phosphorylated in vitro by CDK-1 and -2 on serine residue 120, which is conserved in all hHR6A homologues, leading to an increase in the ubiquitin-conjugating activity of this enzyme. Phosphorylation of hHR6A Ser120 is increased during the G2/M phase of the cell cycle when ubiquitylation of its known substrate, histone H2B, is also increased. Site-directed mutagenesis studies identify Ser120 as a critical regulatory site for hHR6A ubiquitin-conjugating activity, and genetic studies demonstrate that this site is important for the in vivo function of this enzyme. These studies provide the first evidence of UBC regulation by phosphorylation on a conserved residue and suggest an interplay between CDKs and hHR6A to mediate cell cycle progression. Results hHR6A is phosphorylated by cyclin–CDKs in vitro and during the G2/M phase of the cell cycle in vivo In order to identify potential CDK substrates, we used purified cyclin A–CDK2 to perform phosphorylation screening (Fukunaga and Hunter, 1997) of a λ phage breast epithelial cell cDNA expression library (Daly et al., 1996). From a screen of 50 000 clones, ∼100 positive clones were identified. Of these, 30 were sequenced, identifying 16 substrates, including the previously described CDK substrate nucleolar protein B23 (Peter et al., 1990; Okuda et al., 2000). We chose to study further a clone encoding hHR6A, also referred to as UBC2 (Koken et al., 1991), since previous work has implicated a cell cycle role for this UBC (Ellison et al., 1991). The consensus phosphorylation sequence for CDKs is a phosphorylated serine or threonine residue immediately flanked by a proline residue C-terminal to the phosphorylated site (Nigg, 1993). Examination of the hHR6A amino acid sequence revealed four potential CDK phosphorylation sites, including threonine residues 3 and 47 and serine residues 97 and 120 (Figure 1). Sequence alignment of the two human RAD6 homologues, hHR6A and hHR6B, with Rad6 homologues from other species showed that Thr47 and Ser120 are entirely conserved, suggesting that these residues may be important for function (Figure 1). Figure 1.hHR6A CDK consensus phosphorylation sites and aligned sequences of hHR6A homologues. The CDK consensus phosphorylation sites on hHR6A are boxed. The sequence representing identical amino acids of hHR6A and its homologues, including human RAD6B (hHR6B), Drosophila melanogaster, Neurospora crassa, S.cerevisiae and Schizosaccharomyces pombe Rad6, is in bold and italicized. Download figure Download PowerPoint To evaluate which cyclin–CDKs phosphorylate hHR6A, recombinant purified hHR6A was phosphorylated with different cyclin–CDKs in vitro. hHR6A was phosphorylated efficiently by cyclin E–CDK2, cyclin A– CDK2, cyclin A–CDC2 and cyclin B–CDC2, but not by cyclin D1–CDK4, when compared with the ability of these kinases to phosphorylate the retinoblastoma protein, a physiological CDK substrate (Grana and Reddy, 1995) (Figure 2A). To determine whether hHR6A was also a phosphoprotein in vivo, we constructed a mammalian expression vector containing hHR6A with an N-terminal FLAG epitope tag. Transient transfection of Chinese hamster ovary (CHO) cells and [32P]phosphate labelling followed by anti-FLAG immunoprecipitation of the expressed hHR6A showed that hHR6A was phosphorylated in vivo (Figure 2B). Phosphorylation of hHR6A was dramatically reduced in the presence of the CDK-1 and -2 inhibitor roscovitine (50 μM) (Meijer et al., 1997) (Figure 2B), indicating that hHR6A phosphorylation in vivo is dependent on cyclin–CDK activity. To determine whether hHR6A is phosphorylated during a particular cell cycle phase, CHO cells transfected with hHR6A were arrested at the G2/M phase of the cell cycle with nocodazole and then induced to re-enter the cell cycle by nocodazole removal. Analysis of DNA content by flow cytometry showed that nocodazole treatment arrested >90% of the cells in G2/M phase (Figure 2C). Following nocodazole removal, the cells initiated synchronous cell cycle progression, peaking in G1 and S phases at 3 and 9 h, respectively, and progressing through G2 after 12 h. Analysis of hHR6A phosphorylation revealed maximal phosphorylation during the G2/M cell cycle phase (Figure 2D). Interestingly, a phosphoprotein co-immunoprecipitating with hHR6A and migrating several kilodaltons slower was also observed. The identity of this phosphoprotein whose phosphorylation peaked during the S/G2 cell cycle phase is currently under investigation. Figure 2.hHR6A is a CDK substrate in vitro and is phosphorylated during the G2/M cell cycle phase in vivo. (A) Purified His6-hHR6A (top panel) or GST–pRb773−928 (bottom panel) was incubated in the presence of [γ-32P]ATP, in either the absence (Control) or presence of purified cyclin D1–CDK4, cyclin E–CDK2, cyclin A–CDK2, cyclin A–CDK1 or cyclin B–CDK1, resolved by SDS–PAGE and visualized by autoradiography. (B) CHO cells transfected with either pCMV-Tag2 vector (Control) or pCMV-Tag2-hHR6A (hHR6A) were labelled with [32P]phosphate and incubated with either dimethylsulfoxide (left and middle lanes) or 50 μM roscovitine (right lane) during the labelling period. Following labelling, hHR6A was immunoprecipitated, separated by SDS–PAGE and visualized by autoradiography. (C) CHO cells transfected with pCMV-Tag2-hHR6A (hHR6A) were synchronized by blocking in the G2/M cell cycle phase with nocodazole, then initiated to re-enter the cell cycle by nocodazole removal, harvested at various time points for DNA analysis by flow cytometry, and the proportion of cells in G1, S and G2M phases determined. (D) CHO cells transfected with either pCMV-Tag2 vector (Control) or pCMV-Tag2-hHR6A (hHR6A) were synchronized by blocking in the G2/M cell cycle phase with nocodazole (time = 0), initiated to re-enter the cell cycle by nocodazole removal and then lysed at various time points (as indicated). The cells were pulse-labelled with [32P]phosphate for 3 h prior to lysis. Following lysis, hHR6A was immunoprecipitated, separated by SDS–PAGE and visualized by autoradiography (upper panel) or western blotting with an anti-FLAG antibody (lower panel). Phosphorylated hHR6A and the co-immunoprecipitating phosphoprotein (asterisk) are indicated with arrows. Download figure Download PowerPoint hHR6A is phosphorylated on Ser120 in vivo and on the same site by cyclin–CDKs in vitro Since hHR6A is phosphorylated during the G2/M phase, we sought to determine whether it is phosphorylated on cyclin–CDK consensus phosphorylation site(s). This was addressed by expressing wild-type and phospho-site mutant hHR6As in [32P]phosphate-labelled CHO cells which were analysed by phosphoamino acid analysis and tryptic phosphopeptide mapping. Phosphoamino acid analysis showed that hHR6A is phosphorylated exclusively on serine in vivo (Figure 3A, upper panel). Since hHR6A contains two potential serine cyclin–CDK phosphorylation sites at residues 97 and 120 (Figure 1), we mutated these amino acids individually to alanine (S97A and S120A) and analysed hHR6A phosphorylation by tryptic phosphopeptide mapping. These studies demonstrated that wild-type hHR6A generated one major phosphopeptide (Figure 3B, upper panel). While the S97A mutant yielded an identical map, this phosphopeptide was abolished in the S120A mutant, indicating that Ser120 is the major phosphorylation site of hHR6A in vivo. Figure 3.hHR6A is phosphorylated on Ser120 in vivo and on the same site by cyclin A–CDK2 in vitro. (A) Wild-type hHR6A was transfected into CHO cells. Following [32P]phosphate labelling, hHR6A was immuno precipitated and phosphoamino acid analysis performed (upper panel, In vivo). Recombinant purified wild-type hHR6A was phosphorylated in vitro with cyclin A–CDK2 and subjected to phosphoamino acid analysis (lower panel, In vitro). The positions of phosphoserine (P-Ser), phosphothreonine (P-Thr) and phosphotyrosine (P-Tyr) are indicated with arrows. (B) Wild-type, S97A or S120A hHR6A was transfected into CHO cells. Following [32P]phosphate labelling, hHR6A was immunoprecipitated and subjected to tryptic phosphopeptide mapping (upper panels, In vivo). Recombinant purified wild-type, S120A or T3A hHR6A was phosphorylated with cyclin A–CDK2 in vitro and subjected to tryptic phosphopeptide mapping (lower panels, In vitro). The major phosphopeptides are indicated with arrows. The origin is labelled ‘o’. Download figure Download PowerPoint Since hHR6A has four potential cyclin–CDK phosphorylation sites (Figure 1), we phosphorylated purified recombinant wild-type and phospho-site mutant hHR6As with cyclin–CDKs in vitro to confirm that Ser120 is phosphorylated. Phosphoamino acid analysis revealed that hHR6A was phosphorylated in vitro on serine and threonine by cyclin A–CDK2 (Figure 3A, lower panel). Phosphorylation of wild-type hHR6A with cyclin A– CDK2 generated four major tryptic phosphopeptides (Figure 3B, lower panel). Phosphorylation of S120A hHR6A resulted in the loss of phosphopeptide 1, indicating that this phosphopeptide results from phosphorylation of Ser120. Since hHR6A is also phosphorylated on threonine in vitro, we mutated Thr3 to alanine (T3A) to determine whether this site is phosphorylated. Phosphorylation of hHR6A T3A resulted in the loss of phosphopeptides 2–4, indicating that Thr3 is also phosphorylated by cyclin A–CDK2 in vitro. The same data were obtained when hHR6A was phosphorylated with cyclin E–CDK2, cyclin A–CDK1 or cyclin B–CDK1 (data not shown). The generation of three phosphopeptides from phosphorylation of Thr3 is probably due to the generation of partial digests by tryptic cleavage at arginine residues 6–8 (Figure 1). These studies therefore reveal that hHR6A Ser120 and Thr3 are phosphorylated by CDK-1 and -2 in vitro. Cyclin–CDK-mediated phosphorylation of hHR6A Ser120 increases its ubiquitin-conjugating activity in vitro In order to define whether there are any functional consequences on hHR6A ubiquitin-conjugating activity following CDK phosphorylation, we established a two-step phosphorylation/ubiquitylation assay. Purified hHR6A was first phosphorylated by cyclin A–CDK2 and then assayed for its ubiquitin-conjugating activity towards histone H2A, a known in vitro substrate of Rad6 (Sung et al., 1988). Following phosphorylation of hHR6A and prior to initiation of ubiquitylation, the cyclin A–CDK2 was removed by immunodepletion with an anti-CDK2 antibody (data not shown), to ensure that any change in ubiquitylation was not due to phosphorylation of other components in the ubiquitylation reaction, such as E1 or histone H2A. These studies revealed that the level of histone ubiquitylation was increased 4-fold when hHR6A was phosphorylated by cyclin A–CDK2 (Figure 4A, upper panel), in addition to an increased level of hHR6A auto-ubiquitylation (Figure 4A, lower panel). Figure 4.Ser120 is critically important for ubiquitin-conjugating activity, and phosphorylation of this site increases hHR6A activity in vitro. (A) hHR6A was either unphosphorylated (lanes 1, 3, 4 and 6) or phosphorylated with cyclin A–CDK2 (lane 2). Following phosphorylation, cyclin A–CDK2 was immunodepleted and the ubiquitylation reaction performed. Lanes 3–6 are control lanes lacking histone H2A, GST–ubiquitin, hHR6A and E1, respectively (upper panel). hHR6A was either unphosphorylated or phosphorylated with cyclin A–CDK2 (as indicated) and the ubiquitylation reaction performed for either 20, 40 or 60 min (lower panel). Ubiquitylated histone H2A (H2A-Ub) and auto-ubiquitylated hHR6A (hHR6A-Ub) are indicated with arrows. (B) The ubiquitylation activity of wild-type, S120A, S120T, S120D and S120E hHR6As towards histone H2A. Ubiquitylated histone H2A (H2A-Ub) is indicated with an arrow. (C) Wild-type or S120E hHR6A was either unphosphorylated or phosphorylated with cyclin A–CDK2 (A/CDK2). Following phosphorylation, cyclin A–CDK2 was immunodepleted and the ubiquitylation reaction performed (30 min for wild-type hHR6A and 60 min for S120E hHR6A). Ubiquitylated histone H2A is indicated with an arrow. Download figure Download PowerPoint We next sought to determine whether this increase in ubiquitin-conjugating activity was due to phosphorylation of hHR6A Ser120, since cyclin A–CDK2 phosphorylated both Ser120 and Thr3 in vitro. To determine the importance of Ser120 to hHR6A ubiquitin-conjugating activity, we generated hHR6A mutants where Ser120 was substituted for either threonine (S120T), alanine (S120A), aspartate (S120D) or glutamate (S120E). The rationale for generating these mutations was that S120A, S120D and S120E represent mutants that cannot be phosphorylated at this site and therefore should not be activated by cyclin A– CDK2, while substitution to the closely related threonine represents hHR6A similar to the wild-type form. The S120D mutant was generated potentially to mimic phosphorylated serine, due to the negatively charged carboxyl group on aspartate. The S120E mutant was generated to determine whether the conformation and size in addition to the charge of the side group was important for activity, since the carboxyl-containing side group of glutamate is larger than aspartate. Substitution of Ser120 to alanine or threonine almost completely abolished the ubiquitin-conjugating activity of hHR6A (Figure 4B). The S120E mutant displayed 35% of the activity of wild-type hHR6A. Conversely, the S120D mutant displayed 3-fold higher activity than wild-type hHR6A, similar to the 4-fold increase observed following phosphorylation of hHR6A (Figure 4B). These data indicate that a negative charge in this position is preferred, consistent with the notion that introduction of a negative charge at this site by phosphorylation of serine is responsible for increased hHR6A ubiquitin-conjugating activity. Interestingly, the S120D hHR6A mutant was 9-fold more active than the S120E mutant despite their similar structures, demonstrating that the size and conformation of the side group at position 120 are also important determinants of hHR6A ubiquitin-conjugating activity. To confirm directly that phosphorylation of this site by cyclin A–CDK2 is responsible for the increased ubiquitin-conjugating activity of hHR6A, we measured the ubiquitin-conjugating activity of the S120E mutant that cannot be phosphorylated on this site. These studies revealed that phosphorylation of wild-type and not S120E hHR6A by cyclin A–CDK2 resulted in increased ubiquitin-conjugating activity (Figure 4C), confirming that this is due to phosphorylation of Ser120. Histone H2B ubiquitylation is increased in vivo during the G2/M phase of the cell cycle Since our studies demonstrated that phosphorylation of hHR6A Ser120 can increase its ubiquitin-conjugating activity in vitro, we sought to determine whether increased hHR6A phosphorylation during G2/M phase leads to increased substrate ubiquitylation in vivo. We analysed the level of histone H2B ubiquitylation since previous studies have shown that, while Rad6 can ubiquitylate both histones H2A and H2B in vitro (Sung et al., 1988), ubiquitylation of histone H2B is Rad6 dependent in S.cerevisiae (Robzyk et al., 2000). Basic nuclear proteins containing histones were prepared from CHO cells at different stages of the cell cycle, and histone H2B was analysed by immunoblotting. Immunoblotting with an anti-histone H2B antibody revealed the presence of a major immunoreactive band migrating at ∼22 kDa at all cell cycle stages, corresponding to unmodified histone H2B (Figure 5, upper panel). Another band migrating at ∼29 kDa was also detected, corresponding to the predicted size of mono-ubiquitylated histone H2B. Unlike the 22 kDa unmodified histone H2B where levels were invariant at the different cell cycle stages, the level of the 29 kDa band was significantly increased in G2/M phase cells. To confirm that this band represents ubiquitylated histone H2B, we also performed immunoblotting of the same histone preparations with an anti-ubiquitin antibody (Figure 5, lower panel). These results demonstrated that the 29 kDa protein recognized by the histone H2B antibody was also cross-reactive with a ubiquitin antibody and, in agreement with the anti-histone H2B immunoblot, the intensity of this band was significantly increased at the G2/M cell cycle phase. These results demonstrate that ubiquitylation of the known Rad6 substrate, histone H2B, is increased during the G2/M phase, supporting the view that CDK-mediated phosphorylation and activation of hHR6A during this cell cycle phase (Figure 2) leads to increased histone H2B ubiquitylation. Figure 5.Increased ubiquitylation of histone H2B during the G2/M cell cycle phase. CHO cells were synchronized by blocking in the G2/M cell cycle phase with nocodazole, then initiated to re-enter the cell cycle by nocodazole removal, harvested at various time points (as indicated) and histones prepared. Histones were separated by SDS–PAGE and then western blotted with an anti-histone H2B (top panel) or anti-ubiquitin antibody (lower panel). Download figure Download PowerPoint hHR6A Ser120 is critical for cellular proliferation To determine whether Ser120 is important for hHR6A function in vivo, we adopted a genetic approach using S.cerevisiae, since previous work has shown that hHR6A can functionally complement some functions of the yeast homologue, Rad6 (Koken et al., 1991). We tested wild-type and mutant hHR6As for complementation of the RAD6 cell proliferation phenotype, since S.cerevisiae lacking Rad6 display a markedly reduced rate of cellular proliferation due to defects in cell growth and cell cycle progression (Ellison et al., 1991; Freiberg et al., 2000). Wild-type, S120A, S120T, S120D or S120E mutants of hHR6A were transformed into S.cerevisiae rad6Δ, lacking the yeast RAD6 gene. Immunoblotting of lysates prepared from the transformants revealed that all forms of hHR6A were expressed to equivalent levels at either 30 or 37°C (Figure 6A). The growth of the transformants was then tested at 30 and 37°C, since the proliferative defect of S.cerevisiae lacking Rad6 is significantly more pronounced at 37°C (Ellison et al., 1991; McDonough et al., 1995; Freiberg et al., 2000). These studies showed that at 30°C the wild-type S.cerevisiae and all of the S.cerevisiae rad6Δ transformants grew at a similar rate (Figure 6B). However, at 37°C, the S.cerevisiae rad6Δ strain transformed with empty plasmid displayed significantly reduced growth. The S.cerevisiae rad6Δ transformants expressing S120A or S120T hHR6A also grew poorly and at the same rate as the S.cerevisiae rad6Δ strain transformed with plasmid vector alone. Conversely, the transformants expressing wild-type and S120D hHR6A restored the growth of the S.cerevisiae rad6Δ strain to a similar extent to that of wild-type S.cerevisiae. Interestingly, the transformant expressing S120E hHR6A grew at an intermediate rate. Therefore, the ability of the wild-type and hHR6A mutants to complement the proliferative defect of the S.cerevisiae rad6Δ strain at 37°C paralleled their ubiquitin-conjugating activity (Figure 4B), suggesting that modulating hHR6A enzymatic activity is important for controlling the rate of cellular proliferation. Figure 6.Complementation of the S.cerevisiae rad6Δ growth defect with wild–type and mutant alleles of hHR6A. The S.cerevisiae rad6Δ strain was transformed with either empty plasmid or plasmid expressing either wild-type, S120A, S120T, S120D or S120E hHR6A. (A) The expression of wild-type and mutant hHR6As in S.cerevisiae rad6Δ. Lysates were prepared from either wild-type S.cerevisiae (RAD6) or the S.cerevisiae rad6Δ transformants grown at either 30 (top panel) or 37°C (lower panel). Equal amounts of protein were separated by SDS–PAGE, transferred to nitrocellulose and immunoblotted using an anti-hHR6A polyclonal antibody. (B) Wild-type S. cerevisiae (RAD6) or S.cerevisiae rad6Δ transformants were grown at either 30 or 37°C. Ten-fold serial dilutions (from left to right) of exponential phase cultures were spotted on plates and incubated at the indicated temperatures. Download figure Download PowerPoint Discussion In this study, we used a phosphorylation screening approach to identify hHR6A as a CDK substrate. This method has been utilized previously to identify physiological protein kinase substrates including the MAPK substrate MNK1 (Fukunaga and Hunter, 1997) and the CDK substrate PRC1 (Jiang et al., 1998). Using cyclin A– CDK2, we isolated 16 substrates from a partial screen of a breast epithelial cell cDNA library, including the known CDK substrates nucleophosmin/B23 (Okuda et al., 2000) and topoisomerase II (Cardenas et al., 1992). This study characterizes hHR6A, since previous work has shown that the hHR6A yeast homologue, Rad6, is implicated in regulation of cell cycle progression (Ellison et al., 1991) and functions in DNA repair (Koken et al., 1991). Since CDKs are essential for cell cycle progression and in the initiation and completion of DNA synthesis, this raised the possibility that hHR6A function may be regulated by CDK-mediated phosphorylation during the cell cycle. Since we isolated hHR6A using an in vitro phosphorylation screen, we sought to determine whether hHR6A is a phosphoprotein in vivo, and whether it is phosphorylated on CDK consensus phosphorylation sites. Phosphoamino acid analysis of hHR6A transfected into CHO cells revealed that the protein was phosphorylated exclusively on serine residues, and mutation of the two potential serine CDK consensus phosphorylation sites revealed that Ser120 was phosphorylated in vivo. The CDK-1 and -2 inhibitor roscovitine (Meijer et al., 1997) significantly decreased phosphorylation of Ser120 in vivo, indicating that phosphorylation was CDK mediated. Analysis of hHR6A phosphorylation in synchronized cells demonstrated that phosphorylation was dramatically increased during the G2/M phase of cell cycle transition. Interestingly, in addition to Ser120, cyclin A–CDK2 also phosphorylated Thr3 in vitro. The reason for this differential phosphorylation in vivo and in vitro is unclear, but may be due to other proteins interacting with hHR6A at or near potential phosphorylation sites to preclude their phosphorylation by CDKs in vivo. Support for this concept comes from studies showing that the N-terminal amino acids 1–9 of Rad6 bind to the Ubr1 E3 protein in vivo (Watkins et al., 1993). A recent study showing that protein kinase A phosphorylates free histone H3 but not when i
Referência(s)